| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 42,0 k € | -75.2% | 169,4 k € | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||
| Gross margin | -111,5 k € | -37.3% | -81,2 k € | +74.2% | -314,3 k € | -251.6% | 207,3 k € | -75.3% | 838,3 k € | +408.1% | -272,1 k € | -183.4% | 326,1 k € | +4385.1% | -7,6 k € | +87.3% | -60,1 k € | -1200.2% | -4,6 k € | -4.8% | -4,4 k € | +80.9% | -23,1 k € | -120.7% | -10,5 k € | -108.2% | 126,9 k € | -51.9% | 263,8 k € | +1098.2% | 22,0 k € | +1507.9% | -1,6 k € | |
| EBITDA | -114,4 k € | -38.8% | -82,4 k € | +73.9% | -316,0 k € | -255.0% | 203,9 k € | -18.0% | 248,7 k € | +144.2% | -563,1 k € | -273.2% | 325,1 k € | +1262.4% | -28,0 k € | +54.4% | -61,4 k € | -989.4% | -5,6 k € | +7.5% | -6,1 k € | +82.3% | -34,4 k € | -162.5% | -13,1 k € | -111.7% | 112,2 k € | -8.9% | 123,1 k € | +275.4% | -70,2 k € | -268.9% | -19,0 k € | |
| Operating profit | -119,6 k € | +3.4% | -123,8 k € | +63.8% | -342,0 k € | -333.1% | 146,8 k € | -28.9% | 206,4 k € | +135.0% | -590,0 k € | -284.1% | 320,5 k € | +1807.9% | -18,8 k € | +78.8% | -88,7 k € | -186.1% | -31,0 k € | +1.9% | -31,6 k € | +47.2% | -59,9 k € | -9.7% | -54,6 k € | -202.4% | 53,3 k € | -37.6% | 85,4 k € | +182.5% | -103,6 k € | -98.2% | -52,3 k € | |
| Profit/loss | -128,2 k € | -1.8% | -126,0 k € | +64.0% | -350,3 k € | -340.6% | 145,6 k € | -29.2% | 205,8 k € | +134.5% | -596,3 k € | -281.3% | 328,9 k € | +407.7% | 64,8 k € | +926.8% | -7,8 k € | -119.4% | 40,4 k € | +19.2% | 33,9 k € | -91.6% | 402,7 k € | +302.5% | 100,0 k € | +467.9% | 17,6 k € | -78.6% | 82,3 k € | +175.2% | -109,4 k € | -92.6% | -56,8 k € | |
| Equity | 5,5 M € | -2.3% | 5,6 M € | -2.2% | 5,8 M € | +399.9% | 1,2 M € | +14.5% | 1,0 M € | +25.7% | 801,4 k € | -63.6% | 2,2 M € | +52.9% | 1,4 M € | +4.7% | 1,4 M € | -0.6% | 1,4 M € | +3.0% | 1,3 M € | +2.6% | 1,3 M € | +44.5% | 905,2 k € | +12.4% | 805,2 k € | +479.1% | -212,4 k € | +27.9% | -294,7 k € | -59.1% | -185,3 k € | |
| Total assets | 5,6 M € | -0.8% | 5,7 M € | -2.8% | 5,8 M € | +402.0% | 1,2 M € | -1.9% | 1,2 M € | -34.7% | 1,8 M € | -17.6% | 2,2 M € | -0.3% | 2,2 M € | +2.9% | 2,1 M € | +18.9% | 1,8 M € | +2.2% | 1,8 M € | -26.3% | 2,4 M € | +23.6% | 1,9 M € | -10.7% | 2,2 M € | +265.6% | 593,2 k € | +13.3% | 523,5 k € | +19.4% | 438,4 k € | |
| Cash | 198,5 k € | +463.8% | 35,2 k € | -68.3% | 111,2 k € | +0.6% | 110,5 k € | -67.3% | 338,1 k € | +251.9% | 96,1 k € | +95060.5% | 101,0 € | -90.3% | 1,0 k € | -18.8% | 1,3 k € | -7.2% | 1,4 k € | +137.9% | 578,0 € | -81.3% | 3,1 k € | -11.8% | 3,5 k € | -93.8% | 56,2 k € | +39.3% | 40,4 k € | -48.7% | 78,7 k € | +8.3% | 72,6 k € | |
| Debts | 117,8 k € | +228.7% | 35,8 k € | -51.7% | 74,2 k € | +636.8% | 10,1 k € | -94.3% | 177,7 k € | -82.4% | 1,0 M € | +418162.5% | 242,0 € | -100.0% | 767,4 k € | -0.3% | 769,6 k € | +82.9% | 420,7 k € | -0.4% | 422,4 k € | -61.1% | 1,1 M € | +5.3% | 1,0 M € | -24.4% | 1,4 M € | +69.3% | 805,6 k € | -1.5% | 818,2 k € | +36.8% | 598,1 k € | |
| Staff | — | — | — | — | 0,9 | 8,6 | — | — | — | — | — | — | — | 1,9 | 3,2 | 2,8 | 1,4 | |||||||||||||||||
Public limited company · Gent · incorporated on 29/12/1995
Public limited company loss-making in the latest fiscal year. Cash position rising (+463.8%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
RNA Pioneering is a Public limited company incorporated in 1995. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Gent.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette